• Mammotome Fellows Ad x
  • QuestionOfTheWeek Banners x
  • 19 SSO 014 Digital Banners MembershipBanner 1150x135 v5
  • SSO Mobile App Website Top 1150x135 Banner

ADVERTISEMENT

Global Header

Annals of Surgical Oncology

HIGHLIGHTED ARTICLES FROM ANNALS OF SURGICAL ONCOLOGY

Weekly Update

One-Year Experience of Same-Day Mastectomy and Breast Reconstruction Protocol

One Year Experience of Same Day Mastectomy and Breast Reconstruction Protocol

August 11, 2022

Specht, M.C., Kelly, B.N., Tomczyk, E. et al. One-Year Experience of Same-Day Mastectomy and Breast Reconstruction Protocol. Ann Surg Oncol 29, 5711–5719 (2022). https://doi.org/10.1245/s10434-022-11859-9

Synopsis:  A same-day mastectomy recovery protocol was implemented March 2020 at the authors’ institution. Postoperative recovery course was compared to a historical mastectomy cohort. Median length of stay was reduced from 24.5 hours to 5.5 hours, and overnight admissions decreased by 65.8%.

Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin

August 11, 2022

Martin, R.C.G., Simo, K.A., Hansen, P. et al. Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin. Ann Surg Oncol 29, 5462–5473 (2022). https://doi.org/10.1245/s10434-022-11932-3

Synopsis:  The authors hypothesized that delivering irinotecan in drug-eluting beads via the hepatic artery would reduce systemic exposure while targeting to the location of the intra-hepatic cholangiocarcinoma of the liver. Combination Gem/Cis with DEBIRI is safe, and leads to significant improvement in downsizing to resection, improved progression-free survival, and overall survival.

Drug Eluting Bead Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma with Concomitant Systemic Gemcitabine and Cisplatin

Listen to the ASO's new podcast, Speaking of SurgOnc®

Speaking of SurgOnc Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).

The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.

Listen to the podcast here.

ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.

Join the conversation! Follow the journal on Twitter and Facebook. Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.

Scroll to Top